NASDAQ$PODD

Insulet Corp. · Q1 2020 earnings

Q1 2020 earnings · · Investor relations

Briefing

Insulet experienced revenue increase and total Omnipod revenue growth in the first quarter of 2020.

Insulet Corporation reported a strong first quarter in 2020, with revenue reaching $198.0 million, a 24.1% increase year-over-year. Total Omnipod revenue grew by 32.7% to $189.7 million. The company's gross margin was 64.1%, and adjusted EBITDA was $24.3 million, representing 12.3% of revenue. However, the company experienced a net loss of $2.1 million, or $(0.03) per diluted share.

  • Revenue increased by 24.1% year-over-year to $198.0 million, exceeding guidance.
  • Total Omnipod revenue grew by 32.7% to $189.7 million.
  • U.S. Omnipod revenue increased by 35.4% to $116.6 million.
  • Gross margin was 64.1%, impacted by COVID-19 related costs.

Headline financials

Total Revenue

$198M

Previous: $160M+24.1%
EPS (adj)

-$0.03

Previous: $0.07-142.9%
Gross Margin

64.1%

Previous: 66.9%-4.2%
Adjusted EBITDA

$24.3M

Previous: $20.4M+19.1%
Capital Expenditures

-$26.9M

Previous: -$45.3M+40.6%
Free Cash Flow

-$29M

Previous: -$40.9M+29.1%
Net Income

-$2.1M

Previous: $4.38M-148.0%
Operating Income

$7.5M

Previous: $7.27M+3.2%
Gross Profit

$127M

Previous: $107M+18.9%
Cash & Equivalents

$201M

Previous: $129M+55.8%
Total Assets

$1.11B

Previous: $953M+16.3%
Stock-Based Comp

$7.9M

Previous: $5.8M+36.2%

Revenue & EPS history

Insulet · Revenue · Quarterly

$198M

Q1 2020+24.1%vs Q1 2019
Beat estimate in 8 of 16 quarters(50%)
ActualEstimate

Revenue by segment

Insulet · $198M total across 3 segments · Q1 2020

  • U.S. Omnipod
    $117M+35.4%
  • International Omnipod
    $73.1M+28.5%
  • Drug Delivery
    $8.3M-50.0%

Forward guidance

Insulet expects strong revenue growth to continue in the second quarter but anticipates the most significant impact in the second half of 2020, due to the COVID-19 pandemic and recessionary headwinds.

Tailwinds

  • Recurring revenue model provides a benefit.
  • Strong revenue growth is expected to continue in Q2.
  • Company assumes gradual recovery starting in Q3.
  • Total Omnipod revenue is expected to grow.
  • U.S. Omnipod revenue is expected to increase.

Headwinds

  • Progression of COVID-19 is difficult to predict.
  • Significant impact on new global Omnipod starts in Q2.
  • Pandemic and recessionary headwinds expected to persist.
  • Revenue growth will be most impacted in the second half of 2020.
  • Drug Delivery revenue is expected to decline.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports · overlaid with Q1 2020

Historical avgQ1 2020

+3.0%

Avg return

Earnings day

+4.0%

Avg return

5 days after

+5.2%

Avg return

30 days after

65%

41 / 63 earnings

Positive

+20.7%

Q1 2025

Best reaction

-16.8%

Q1 2022

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026-1.1%+3.8%+1.4%
Q4 2025+3.5%+1.2%-7.8%
Q3 2025+2.8%+3.8%-3.2%
Q1 2025+20.7%+25.1%+21.3%
Q4 2024-1.9%-6.1%-6.9%
Q3 2024+12.0%+15.0%+10.9%
Q2 2024-4.3%+2.2%+12.8%
Q1 2024-5.5%-1.9%+9.0%
Q4 2023-4.3%-13.4%-14.6%
Q3 2023+18.1%+17.5%+39.6%
Q2 2023-11.9%-13.6%-31.6%
Q1 2023+2.4%-0.4%-12.4%
Q4 2022+2.3%-4.0%+7.8%
Q3 2022+19.6%+16.3%+17.7%
Q2 2022+2.4%-0.8%-2.5%
Q1 2022-16.8%-23.0%-13.9%
Q4 2021+8.9%+12.9%+7.4%
Q3 2021-1.3%+2.0%-15.6%
Q2 2021-1.3%+0.1%+8.4%
Q1 2021-11.4%-13.0%+2.8%
Q4 2020+2.3%+1.0%+1.0%
Q3 2020+14.6%+14.4%+16.0%
Q2 2020+1.1%-7.7%-4.9%
Q1 2020+5.4%+6.8%-13.3%
Q4 2019-13.2%-8.4%-14.2%
Q3 2019+9.9%+16.4%+26.5%
Q2 2019+18.4%+26.0%+30.0%
Q1 2019+14.0%+20.9%+29.4%
Q4 2018+5.1%+7.7%+6.6%
Q3 2018+0.4%-2.4%-4.9%
Q2 2018+2.4%+2.6%+24.3%
Q1 2018-3.6%-4.3%+9.0%
Q4 2017+3.6%-1.1%+8.6%
Q3 2017+18.9%+22.7%+21.0%
Q2 2017+6.5%+8.6%+15.5%
Q1 2017-5.8%-4.6%+0.9%
Q4 2016-5.2%+0.7%-7.2%
Q3 2016+9.9%+10.3%+3.9%
Q2 2016+18.5%+23.3%+22.2%
Q1 2016-4.0%
Q4 2015+9.0%
Q3 2015+13.2%
Q2 2015+10.0%
Q1 2015-11.0%
Q4 2014-4.5%
Q3 2014+5.1%
Q2 2014-2.2%
Q1 2014-14.0%
Q3 2013-3.4%
Q2 2013+10.2%
Q1 2013+12.0%
Q4 2012+9.3%
Q3 2012+4.2%
Q2 2012+4.8%
Q1 2012+2.1%
Q4 2011-3.5%
Q3 2011+0.5%
Q2 2011+2.9%
Q1 2011+0.6%
Q4 2010-2.0%
Q3 2010+2.5%
Q2 2010+0.3%
Q1 2010+11.1%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro